Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sucrase-isomaltase, intestinal (SI), is a bifunctional enzyme located in the brush border membrane of enterocytes in the small intestine[1][3][6]. It consists of two subunits, sucrase and isomaltase, both members of the glycoside hydrolase family 31 (GH31), which are responsible for the final step in the digestion of dietary carbohydrates such as sucrose, isomaltose, and maltose into absorbable monosaccharides[1][2][4]. SI is essential for normal carbohydrate absorption and energy production. Mutations in the SI gene can cause congenital sucrase-isomaltase deficiency, leading to malabsorption and gastrointestinal symptoms[3][5]. SI activity can be inhibited by drugs such as acarbose and miglitol, which are used to slow glucose absorption in diabetes management. Interaction with another enzyme, maltase-glucoamylase, influences carbohydrate digestion efficiency and disease phenotypes in GI syndromes[5][1].
Alpha-glucosidase inhibition (inhibitors reduce enzymatic hydrolysis of disaccharides, slowing glucose absorption)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sucrase-isomaltase, intestinal (SI).